- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03226808
Vivacit-E Post-market Follow-up Study
Post Market Clinical Follow-up Study of the Zimmer Vivacit-E Highly Crosslinked Polyethylene Liner Used With the Continuum Acetabular Shell
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Safety will be evaluated by monitoring the frequency and incidence of adverse events.
Performance will be determined by assessment of the overall pain and functional performances, survivorship, health status and radiographic parameters of all enrolled study subjects who receive the Vivacit-E HXPE Liner with the Continuum acetabular shell.
In addition, the implanted Vivacit-E HXPE Liners will be evaluated for bedding in, and linear and volumetric wear by the Martell 2-D method at 6 weeks and 1, 2, 4, & 5 years postoperatively.
Pain and functional performance will be measured using the Harris Hip and High Activity Arthroplasty Scores. Survivorship will be based on removal or intended removal of the device and through analysis of radiographs, and health status will be determined by evaluation of the EQ-5D.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Parker, Colorado, United States, 80134
- Denver Hip and Knee, Inc.
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Department of Orthopaedics University of North Carolina at Chapel Hill
-
Charlotte, North Carolina, United States, 28207
- OrthoCarolina Research Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Rothman Institute
-
-
Texas
-
Austin, Texas, United States, 78751
- Texas Institute for Hip and Knee Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient is 18 to 60 years of age, inclusive.
- Patient is skeletally mature.
- Patient qualifies for primary unilateral or bilateral total hip arthroplasty (THA) based on physical exam and medical history including at least one of the following:
- Osteoarthritis
- Avascular necrosis (AVN)
- Post-traumatic arthritis
- Congenital hip dysplasia
- Patient has no history of previous total hip replacement or arthrodesis of the affected hip joint(s).
- Patient is willing and able to provide written informed consent.
- Patient is willing and able to cooperate in the required post-operative therapy.
- Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
- Patient has participated in the Informed Consent process and has signed the IRB/EC approved informed consent.
Exclusion Criteria:
- Patient is unwilling or unable to give consent or to comply with the follow-up program.
- Patient has a total prosthetic hip replacement device (including surface replacement arthroplasty, endoprosthesis, etc. in the affected hip joint(s).
- Inflammatory Arthritis
- Rheumatoid Arthritis
The patient is:
- a prisoner mentally incompetent or unable to understand what participation in the study entails a known alcohol or drug abuser
- anticipated to be non-compliant
- The patient has an acute, chronic, or systemic infection(s).
- The patient has total or partial absence of the muscular or ligamentous apparatus.
- The patient has neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation.
- The patient has osteoradionecrosis.
- The patient has lack of bony structures proximal or distal to the operative joint, so that good implant fixation is unlikely or impossible.
- The patient has local bone tumors/cysts in the bone to be retained that the implanting surgeon determines could inhibit implant fixation.
- The patient is skeletally immature.
- The patient has any concomitant disease that can jeopardize the functioning and the success of the implant.
- The patient is known to be pregnant.
- The patient has a known sensitivity or allergic reaction to one or more of the implanted materials which include metal (titanium, tivanium, tantalum, cobalt, chromium, nickel) and ceramic.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Vivacit-E Liner
All subjects enrolled receive the study implant.
|
All subjects enrolled will receive the Vivacit-E liner.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival of the study device; whether or not it is still implanted in the subject
Time Frame: 10 years
|
Survival is classified as removal of the study device for any reason
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent Adverse Events (safety)
Time Frame: 10 years
|
Safety is assessed by monitoring the frequency and incidence of all adverse events, with particular focus on those that may be related to the study device.
|
10 years
|
Harris Hip Score
Time Frame: 10 years
|
Functional outcomes are measured with the Harris Hip Score, including range of motion, pain level, activity levels and patient satisfaction.
|
10 years
|
Patient activity level
Time Frame: 10 years
|
Patient activity level is assessed with the High Activity Arthroplasty score, filled out by the patient.
|
10 years
|
Patient Quality of Life
Time Frame: 10 years
|
This is another self-assessment by means of the EQ-5D score, which measures the patient's perceived quality of life.
|
10 years
|
Radiographic analysis
Time Frame: 2 years
|
Patient x-rays will undergo a Martell analysis by Dr. John Martell to evaluate radiolucencies, osteolysis, sbusidence, cup migration and polyethylene wear.
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ryan Boylan, MBA, Zimmer Biomet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Wounds and Injuries
- Congenital Abnormalities
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Bone Diseases
- Hip Injuries
- Musculoskeletal Abnormalities
- Joint Dislocations
- Osteoarthritis
- Necrosis
- Hip Dislocation
- Developmental Dysplasia of the Hip
- Hip Dislocation, Congenital
- Osteonecrosis
Other Study ID Numbers
- CMU2011-09H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Vivacit-E Liner
-
Zimmer BiometRecruitingOsteoarthritis, Hip | Avascular Necrosis of Hip | Total Hip Arthroplasty | Osteoarthritis of Hip | Fracture of Hip | Degenerative Joint Disease of Hip | Fractures, Hip | Rheumatoid Arthritis of HipDenmark, United States, Sweden, Netherlands, United Kingdom
-
Zimmer BiometEnrolling by invitationRheumatoid Arthritis | Avascular Necrosis | Osteoarthritis, Hip | Femoral Neck Fractures | Dislocation, Hip | Trochanteric Fractures | Non-Union FractureUnited States
-
Zimmer BiometEnrolling by invitationJoint Diseases | Rheumatoid Arthritis | Avascular Necrosis | Femoral Neck Fractures | Hip Osteoarthritis | Dislocation, Hip | Trochanteric Fractures | Revision SurgeriesBelgium, United States, Korea, Republic of, Italy
-
Odense University HospitalMassachusetts General HospitalActive, not recruitingOsteoarthritis | Osteoarthritis, HipDenmark
-
GI DynamicsCompleted
-
GI DynamicsCompleted
-
GI DynamicsBiostatistical Consulting, Inc.Recruiting
-
Hacettepe UniversityUnknownTeeth; Lesion | Dental Root Caries
-
Biomet Nederland BVAtrium Medical CenterTerminatedOsteoarthritisNetherlands